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Peter A. Brady, MD,* Joseph A. Dearani, MD,† Raúl E. Espinosa, MD*
Rochester, Minnesota
Objectives The goal of this study was to determine the impact of transvenous pacemaker and defibrillator leads on the incidence
of bioprosthetic tricuspid valve (BTV) regurgitation compared with BTV patients without a transvalvular lead.
Background Although concern has been raised regarding the potential deleterious effect of permanent transvenous device
leads on BTV function, little is known about the incidence of prosthetic tricuspid regurgitation (TR) after lead
placement.
Methods A retrospective review of 58 patients who underwent BTV implantation and subsequently required endocardial
pacemaker (n  52) or defibrillator (n  6) lead implantation across the BTV was conducted. Patient and pros-
thesis characteristics, lead type, and clinical events were collected. The incidence and severity of prosthetic TR,
determined by Doppler echocardiography, was compared with 265 consecutive patients who underwent BTV im-
plantation without undergoing subsequent transvalvular device lead implantation.
Results Over a mean follow-up of 25 months, in 5 patients (9%) with a transvalvular lead significant (moderate or
greater) prosthetic TR developed compared with 12 patients (5%) in the control group (p  0.20). Kaplan-Meier
analysis revealed no significant difference in the incidence of TR in BTV patients with and without transvalvular
leads (p  0.45). Significant prosthetic TR in patients with and without a transvalvular lead more commonly oc-
curred 2 years or later after lead or BTV implantation (4 of 5, 80% and 10 of 12, 83%, respectively).
Conclusions Transvalvular device lead implantation in BTV patients was not associated with an increased incidence of
significant prosthetic TR (p  0.45). Based on these data, transvalvular lead implantation appears to be an
acceptable approach for patients with a BTV who require permanent pacemaker or defibrillator placement.
(J Am Coll Cardiol 2012;59:813–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.893Tricuspid valve replacement (TVR) with a bioprosthetic tri-
cuspid valve (BTV) is an established treatment for severe
tricuspid valve (TV) stenosis and tricuspid regurgitation (TR)
related to a variety of disease states. Atrioventricular block and
sinus node dysfunction are recognized postoperative compli-
cations in these patients, often necessitating permanent
pacemaker implantation. In some cases, patients at in-
creased risk of sudden cardiac death undergo defibrillator
implantation. In contrast to mechanical TV prostheses, a
bioprosthetic valve can in principle be crossed by trans-
venous leads. Concern has been raised regarding the poten-
tial deleterious effect of permanent transvenous device leads
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accepted October 19, 2011.on bioprosthetic tricuspid valve (BTV) function, yet few
data exist pertaining to outcomes, specifically the occurrence
of significant prosthetic TR after lead placement in this
population.
Concern over transvalvular lead implantation has largely
been derived from data pertaining to the native TV, in
which transvalvular device leads appear to increase the risk
of TR. Severe TR develops in some of these patients (1,2),
with important clinical sequelae, including the development
of right heart failure requiring surgical TV repair or replace-
ment. Several mechanisms contribute to the development of
severe TR in patients with device leads that pass through
the native TV, including leaflet perforation, lead entangle-
ment in the valve apparatus, lead impingement of leaflet
excursion, and lead adherence to the valve (3).
Given the different anatomic structure of BTV, the mech-
anisms of lead-induced native TR may not be entirely relevant
in this population. Most contemporary BTVs are composed of
porcine tissue attached to a plastic and polyester cloth frame
that is anchored to a sewing ring. If device leads were known
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pact on BTV function, alternative
implantation strategies would have
to be considered to avoid long-
term BTV damage and dysfunc-
tion. Lower profile right ventricu-
lar (RV) leads and left ventricular
(LV) pacing via the coronary sinus
might potentially limit BTV dys-
function. The goal of this study
was to determine whether trans-
valvular device leads promote sig-
nificant BTV regurgitation.
Methods
The medical records of all patients who underwent TVR
with a BTV at our institution between January 1, 1997, and
July 1, 2010, were reviewed after approval from the institu-
tional review board. Patients who subsequently underwent
transvalvular endocardial permanent pacemaker or defibril-
lator implantation were included in the study group. The
medical records were reviewed longitudinally, and echocar-
diographic data were recorded. Patients without an echo-
cardiographic follow-up examination after device lead im-
plantation were excluded from the study group. Patients
with preexisting transvenous leads undergoing BTV im-
plantation in whom the ventricular lead was externalized
between the BTV sewing ring and the TV annulus were also
excluded from the study unless they subsequently underwent
transvalvular lead implantation. A control group of patients
who underwent TVR with a BTV and no subsequent
transvalvular lead implantation was also followed longitudi-
nally to determine the incidence and severity of prosthetic
TR. Clinical variables including the indication for TVR,
BTV type and size, concomitant cardiac surgery, indication
for device implantation, transvalvular lead type, and RV lead
implant location were collected for all patients.
2-dimensional and Doppler echocardiography. Trans-
horacic 2-dimensional and Doppler echocardiography was
erformed within 1 week of TVR and at follow-up for all
atients. Echocardiographic studies were performed on com-
ercially available ultrasound equipment (Acuson Sequoia,
iemens Medical, Mountain View, California; Vivid-7, GE
ealthcare, Milwaukee, Wisconsin; and IE33, Phillips
ealthcare, Andover, Massachusetts) according to the stan-
ard methods recommended by the American Society of
chocardiography (4,5). In accordance with these guidelines
5), the severity of TR was graded in the apical 4-chamber view
ased on TR jet length and jet area as estimated by color flow
oppler. TR severity was semiquantitatively classified as triv-
al, mild, moderate, or severe using a standard method (6,7).
ontinuous wave Doppler of the TR signal was recorded and
he peak regurgitant velocity used to estimate RV systolic
ressure using the modified Bernoulli equation. Inferior vena
Abbreviations
and Acronyms
BTV  bioprosthetic
tricuspid valve
LV  left ventricular
RV  right ventricular
TR  tricuspid valve
regurgitation
TV  tricuspid valve
TVR  tricuspid valve
replacementava size and the degree of inspiratory collapse were used to rstimate right atrial pressure. When significant TR was sus-
ected, pulse wave and color Doppler imaging was used to
ssess for alterations in hepatic vein flow patterns as seen in
evere TR (8). RV and right atrial size were visually inspected
nd incorporated into the assessment of TR severity.
Intraoperative transesophageal echocardiography was also
erformed at the time of TVR in all subjects. None of the
atients had more than mild TR immediately after BTV
mplantation.
tatistical analysis. Descriptive statistical analyses were per-
ormed. Data are reported as mean SD or total number and
ercentage. For independent groups (study and control), the
isher exact test was used to compare categorical variables,
hereas the Student t test was used for continuous variables. A
aplan-Meier analysis was performed to compare the inci-
ence of significant TR between the study and control groups.
he log-rank test was used to compare the 2 groups. Statistical
nalysis was performed using SAS software (SPSS version
2.0, SAS Institute Inc., Cary, North Carolina).
esults
ransvalvular lead population. Fifty-eight patients with a
ermanent transvenous endocardial device lead placed across
he BTV were included in the study group. Patient demo-
raphics are shown in Table 1, device lead characteristics in
able 2, and echocardiographic characteristics in Table 3.
ifty-four leads were placed at the RV apex, 3 leads along the
id-RV septum, and 1 lead in the RV outflow tract. All
ndocardial RV leads were steroid-eluting, active fixation
odels. Six of the transvalvular leads (10%) were defibrillator
eads. Twenty-seven of the 58 patients (46%) had concomitant
itral, aortic, or pulmonary valve repair or replacement at the
ime of BTV implantation. The mean clinical and echocardio-
raphic follow-up duration was 752  1,042 days after lead
mplantation. Forty patients (69%) had 30 days of clinical
Characteristics of 323 PatientsWith Bioprosthetic Tricusp d ValvesTable 1 C aracteristics of 323 PatientsWith Bioprosthetic Tricuspid Valves
BTV Lead
(n  58)
BTV Only
(n  265)
p
Value
Age, yrs 65 15 61 17 0.11
Female 40 (69) 164 (62) 0.37
Indication for BTV
TR (carcinoid syndrome) 4 (7) 44 (17) 0.07
TR (Ebstein anomaly) 6 (10) 43 (16) 0.32
TR (other causes) 48 (83) 178 (67) 0.02
BTV type
Carpentier Edwards Perimount 2 (3) 4 (2) 0.29
St. Jude Medical Biocor 21 (36) 123 (46) 0.19
Medtronic Mosaic 5 (9) 57 (22) 0.03
Carpentier Edwards Duraflex 30 (52) 76 (29) 0.001
CarboMedics Mitroflow 0 5 (2) 0.59
BTV diameter, mm 31.6 2.2 31.8 1.9 0.37
Follow-up duration, days 752 1,042 550 734 0.19
Values are mean  SD or n (%).
BTV  bioprosthetic tricuspid valve; Lead  pacemaker or defibrillator lead; TR  tricuspid
egurgitation.
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February 28, 2012:813–8 Lead-Related Bioprosthetic Tricuspid Regurgitationand echocardiographic follow-up after transvalvular lead im-
plantation, with a mean follow-up duration of 1,018  1,046
ays.
mmediate and long-term findings after transvalvular
ead placement. In 5 patients (9%) with a transvalvular lead,
oderate or greater prosthetic TR developed (Fig. 1). Signif-
cant TR developed in none of the patients in the transvalvular
ead group in the first week after BTV implantation. Moderate
r greater TR was detected 1 month after lead implantation in
patient and20 months later in 4 patients. The patient with
arly TR died 3 months after lead implantation of congestive
eart failure due to restrictive cardiomyopathy. The remaining
cases survived 5 years after transvalvular device lead
mplantation, with 1 requiring repeat BTV implantation for
evere TR. In the single patient that underwent repeat BTV
mplantation, pathological examination of the excised biopros-
hesis showed no calcification, cusp tear, thrombus, or obstruc-
ive fibrous ingrowth (pannus).
Device Lead CharacteristicsTable 2 Device Lead Characteristics
Lead type
Pacemaker 52
Defibrillator 6
Lead external insulation
Silicone 30
Polyurethane 23
Copolymer (silicone and polyurethane) 5
Active fixation 58
RV apex 54
RV midseptum/RV outflow tract 4
Lead body size, F
5.7 23
6.0 17
6.2 12
6.8 1
8.2 1
8.6 4
Values are n.
RV  right ventricular.
Echocardiographic and Hemodynamic Variables at Follow-UpTable 3 Echocardiographic and Hemodynamic Variables at Foll
Study Group
Moderate or Less TR
(n  53)
Moderate or
(n 
Body surface area, m2 1.80 0.21 1.78
Ejection fraction, % 56 14 64
LV mass index, g/m2 99 32 114
Bioprosthetic TV mean gradient, mm Hg 5.8 2.1 6.2
TV regurgitant velocity, m/s 2.8 0.5 2.9
Estimated right atrial pressure, mm Hg 11.6 5.0 16.0
Estimated right ventricular
systolic pressure, mm Hg
45 13 51
Systolic blood pressure, mm Hg 117 18 117
Diastolic blood pressure, mm Hg 60 10 72
Heart rate, beats/min 74 16 73Values are mean  SD.
LV  left ventricular; TR  tricuspid regurgitation; TV  tricuspid valve.ontrol population. The control group included 265 pa-
ients who underwent TVR with a BTV and no subsequent
mplantation of a transvalvular device lead. The mean clinical
nd echocardiographic follow-up duration was 554 734 days
fter BTV implantation. Clinical characteristics are shown in
able 1. Age, sex, and follow-up duration were similar in the
ontrol and study groups (all p  0.05) (Table 1). Of the 265
ontrol patients, 63 (24%) had an endocardial RV lead before
VR surgery that was subsequently externalized outside the
ewing ring at the time of BTV implantation. In 4 patients
2%), an epicardial ventricular lead was placed at the time of
VR surgery. High-grade atrioventricular block developed in 6
atients (2%) after BTV implantation, and they underwent
lacement of an LV lead via the coronary sinus to avoid
p
Control Group
r TR
p Value
Moderate or Less TR
(n  253)
Moderate or Greater TR
(n  12) p Value
0.90 1.85 0.26 1.76 0.17 0.09
0.05 57 12 61 11 0.31
0.61 101 34 82 35 0.12
0.42 5.5 2.4 6.3 2.5 0.26
0.59 2.5 0.5 2.6 0.9 0.78
0.15 11.5 5.7 10.8 5.0 0.69
0.44 37 15 40 19 0.66
0.96 116 19 117 16 0.88
0.26 62 11 70 10 0.04
0.85 75 15 70 14 0.30
Figure 1 Incidence of Bioprosthetic TR in Patients With a
Transvalvular Device Lead Compared With Controls
Patients with and without a transvalvular device lead had a similarly low
incidence of prosthetic tricuspid regurgitation (TR) at follow-up (p  0.20).ow-U
Greate
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ing 192 patients (72%) did not require pacemaker or defibril-
lator implantation during the follow-up period.
During follow-up, moderate or greater BTV regurgitation
developed in 12 control group patients (5%). In 10 patients,
Figure 2 Severity of Prosthetic Regurgitation at Follow-Up
Distribution of prosthetic tricuspid regurgitation severity at follow-up
in patients with and without a transvalvular device lead.
Figure 3 Product-Limit Survival Fit Failure Plot for All Subjects
Kaplan-Meier product-limit failure plot for significant prosthetic tricuspid regurgitati
and without transvalvular lead implantation showed no significant difference betwemoderate or greater TR was detected 2 years after BTV
implantation. In 1 patient, TR was detected 1 year after TVR.
In the last patient, moderate TR developed 1 week after BTV
implantation and was probably related to thrombus formation
on the prosthetic valve cusps because echocardiography dem-
onstrated cusp thickening with reduced mobility. This patient
was anticoagulated, and 4 months later, had only mild pros-
thetic regurgitation. The mean clinical follow-up duration for
this group of 12 patients was 563  784 days after the
detection of moderate or greater BTV regurgitation by echo-
cardiography. The majority of patients (n 9, 75%) remained
asymptomatic at follow-up without signs or symptoms of right
heart failure. Three patients required repeat BTV implantation
for symptoms of right heart failure. Of these 3 patients, 1
subsequently underwent LV assist device implantation for
end-stage ischemic cardiomyopathy and died of multiorgan
failure 4 months after the detection of severe TR. The other 2
patients who had repeat BTV implantation were asymptomatic
at follow-up.
Impact of transvalvular device leads on prosthetic TR.
The severity of BTV regurgitation in patients with and
without transvalvular leads is shown in Figure 2. Kaplan-
Meier analysis for the incidence of significant TR in the
study versus control group is shown as a failure plot in
Figure 3. Comparison of the 2 groups revealed no signifi-
cant difference in the incidence of TR (p  0.45). A
reassessment after excluding patients with 30 days of
echocardiographic follow-up (n  18) after transvalvular
lead placement likewise showed no significant difference in
the incidence of TR (Fig. 4) (p  0.19).
) in bioprosthetic tricuspid valve recipients with
2 groups (p  0.45).on (TR
en the
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echocardiographic variables shown in Tables 1 and 2 re-
vealed no significant predictors of TR in the study or control
groups, including prosthetic valve type (p  0.65 and p 
0.46, respectively), indication for TVR (p  0.33 and p 
0.45, respectively), or right ventricular systolic pressure
(p  0.44 and p  0.66).
Discussion
The present study is the first to examine the incidence of
significant prosthetic TR after transvalvular pacemaker or
defibrillator lead implantation in patients with a BTV com-
pared with prosthetic TR in patients who have not undergone
transvalvular lead implantation. In this population, we found
no significant difference in the incidence of early or late
prosthetic TR between the 2 groups over a mean follow-up of
2 years. These results provide reassurance that implantation of
a transvalvular device lead across a BTV does not significantly
increase the risk of prosthetic regurgitation.
The clinical implications of these findings are substantial
because patients who require a pacemaker or defibrillator
after BTV implantation may undergo more complex or less
durable device implantation procedures, such as placement
of an epicardial ventricular lead or transvenous LV lead via
the coronary sinus, in an attempt to avoid damaging the
BTV (9–13). Epicardial leads generally have poorer longev-
ity compared with endocardial leads due to higher chronic
thresholds (i.e., exit block) and lead fracture (12), whereas
the long-term stability of leads placed via the coronary sinus
Figure 4 Product-Limit Survival Fit Failure Plot for Patients Wit
Kaplan-Meier product-limit failure plot for significant prosthetic tricuspid regurgitati
and without transvalvular lead implantation and 30 days of follow-up showed nois less than that of leads placed in a conventional endocardialRV location (14,15). A transvenous endocardial system may
even be placed before TVR and then exteriorized to the
prosthesis at the time of TVR. This exteriorized lead
approach is particularly relevant to defibrillator implanta-
tion, in which endocardial systems with an RV lead are
optimal for the integrity of pacing and defibrillation. Un-
fortunately, such recently placed leads are more prone to
dislodgment intraoperatively and cannot readily be reposi-
tioned. The findings of this study suggest that such efforts to
avoid transvalvular lead placement may be unnecessary.
Our data highlight the fact that BTV regurgitation may
occur early or late, with or without a transvalvular lead,
thereby suggesting varied mechanisms of prosthesis dys-
function. In the present study, there was no increased
incidence of early or late significant BTV regurgitation in
the study group after transvalvular lead implantation com-
pared with controls. In a study of 61 patients with native TV
referred for transvenous device implantation, no significant
worsening in the severity of native TR was noted early after
endocardial lead implantation (16). Furthermore, TR sever-
ity did not change at a mean follow-up of 6  3 months
(16). In another study of patients with severe symptomatic
native TR due to device leads, the average time from
pacemaker or defibrillator placement to TV surgery was 6
years (range: 2 months to 19 years), with lead adherence and
impingement of the tricuspid valve leaflets more common
(30 of 41, 73%) than perforation or entanglement (11 of 41,
27%) (3). The authors did not describe the temporal
evolution of severe TR in their patients and instead empha-
0 Days of Follow-Up
) in bioprosthetic tricuspid valve recipients with
cant difference between the 2 groups (p  0.20).h >3
on (TR
signifisized the obstacles to timely recognition of this disorder. In
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Lead-Related Bioprosthetic Tricuspid Regurgitation February 28, 2012:813–8the one patient in the present study with a transvalvular lead
and severe prosthetic regurgitation who underwent repeat
BTV replacement, pathological examination of the excised
valve was inconclusive regarding the mechanism of TR. The
overall incidence of TR was low in the BTV group with a
transvalvular lead. It is possible that BTV may be less vulner-
able to lead-induced regurgitation than the native TV. They
have smaller and thicker cusps, and glutaraldehyde fixation
may have leaflet-stabilizing properties, potentially contributing
to the observed low incidence of TR in this study.
Study limitations. Although the present study provides
important long-term follow-up data on the incidence of
BTV regurgitation in association with transvalvular pace-
maker or defibrillator leads in a large series of patients,
limitations exist. The data were collected retrospectively,
and only patients with echocardiographic follow-up were
included, which may introduce selection bias. The number
of patients with a transvalvular lead was relatively small, and
event rates were low, which may limit the ability to detect a
statistically significant difference in the incidence of BTV
regurgitation compared with controls. Furthermore, al-
though the mean follow-up duration was favorable, several
patients had relatively short follow-up, which may limit the
capacity of the study to identify a greater tendency for TR
over the long term after device lead implantation. For this
reason, a separate Kaplan-Meier analysis was performed
that included only patients with 30 days of follow-up. A
prospective study with more uniform and longer follow-up
would more accurately quantify the risk of significant BTV
regurgitation in the setting of transvalvular pacemaker or
defibrillator leads, but would also be difficult to perform. In
the current study, the majority (69%) of study group
patients had at least 30 days of follow-up, with a median
follow-up duration of 655 days. As such, it represents a
robust analysis of the incidence of BTV regurgitation in the
first 2 years after transvalvular lead implantation. Further
investigation will be required to more fully judge the
incidence of BTV regurgitation beyond 2 years after lead
implantation. Finally, a relatively small number of defibril-
lator leads were implanted, thus limiting inferences that can
be made regarding the risk of TR from transvalvular
defibrillator leads in this BTV population.
Conclusions
In a group of BTV patients who received transvalvular
pacemaker and defibrillator lead systems postoperatively,
the incidence of moderate or greater prosthetic TR was not
significantly different from that of BTV controls without a
transvalvular lead. Thus, in patients who require a perma-
nent pacemaker or defibrillator after BTV implantation, use
of an endocardial lead system that crosses the BTV appears
to be an acceptable approach.Reprint requests and correspondence: Dr. Mackram F. Eleid,
Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
E-mail: eleid.mackram@mayo.edu.
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